by dtrubin | Jul 29, 2020 | In the Press
Dr. Rubin discusses the three classes of biologic therapies approved for IBD. These therapies, albeit revolutionary for patient care are limited by clearance issues, need for dose escalation, and loss of response. The arrival of small molecule therapies, such as...
by dtrubin | May 22, 2020 | In the Press
The data on COVID-19 is changing rapidly and can be overwhelming. Having been on the frontlines of the pandemic, Dr. David T. Rubin, Dr. Sushila Dalal, and Dr. Miguel Regueiro break down the latest information and best practices for managing patients with IBD and...
by dtrubin | Apr 3, 2020 | In the Press
In light of the COVID-19 pandemic, Dr. Rubin has been active in informing IBD patients what we know, don’t know, and what experts suggest. This HealthCentral article covers “What People With IBD Need to Know about COVID-19”. Dr. Rubin says the...
by dtrubin | Mar 21, 2020 | Coronavirus, Rubin's Reflections
By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine (Posted to IBD-circle.within3.com on March 21, 2020) Colleagues, A question that has come up recently is how we should approach treating active IBD during the SARS-CoV-2 pandemic. Here are my...
by dtrubin | Mar 21, 2020 | Coronavirus, Rubin's Reflections
By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine (Posted to IBD-circle.within3.com on March 21, 2020) Dear Colleagues, I have been fielding lots of questions about whether our IBD patients on immune therapies should stay home from work....
